Overall rank by patents
#27,930
of 49,997 tracked assignees
USPTO PatentsView assignee record - 9 granted patents across 12 technology areas, recorded in grant years 2016–2020. Grant-trend analysis is cross-referenced to USPTO Patent Public Search; it does not measure application filings, current R&D, or legal strength. Primary class: C30B (Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrys).
The verdict
According to USPTO PatentsView, 1366 ranks #27,930 of 49,997 tracked US assignees by granted-patent volume, with 9 patents across 12 technology areas.
USPTO PatentsView assignee plate
Corpus R27930 · US Corporation #27,930 · 9 grants
GRANTS-MICRO · MID-PACK · PHOTO-FINISH · CPC-FOCUS · INNOV-THIN · CLAIMS-RICH · TYPE-USCORP · VEL-DROP · BOOK-FULL
Nearest grant-volume peer: 1004335 Ontario Inc. (±0 grants)
Instrument codes from this assignee’s USPTO PatentsView grant sheet: volume band, corpus rank, photo-finish peer, lead CPC, Innovation Score, claim depth, assignee type, velocity, and book completeness. Not a USPTO rating of patent strength.
Lowest and highest poles plus nearest Innovation Score peers, not a full corpus board reprint.
Qualcomm Incorporated · highest
85 score
1366 · this assignee
32 score
3D Lighting… · lowest
7 score
What this shows 1366's Innovation Score is 31.8/100 (39th percentile of the PatentsView-derived corpus). The chart places that score against the nearest Innovation Score peers plus corpus poles, not a reprint of the volume ranking.
1366 Technologies Inc. is a focused PatentsView assignee: 12 CPC subclasses with 66.7% of grants classified under C30B (Single-crystal Growth ; Unidirectional Solidification OF Eutectic Material OR Unidirectional Demixing OF Eutectoid MATERIAL; Refining BY Zone-melting OF Material ; Production OF A Homogeneous Polycrys). Peak complete grant year is 2020 (3 grants) versus a trough of 1 in 2018. By volume, 1366 sits between viDA Therapeutics Inc. and 3-V Biosciences, Inc..
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
viDA Therapeutics Inc.
10 patents
1004335 Ontario Inc.
9 patents
1010210 B.C. Ltd.
9 patents
1311854 Ontario Limited
9 patents
1929803 Ontario Corp.
9 patents
1A Smart Start LLC
9 patents
2KDirect, Inc.
9 patents
3-V Biosciences, Inc.
9 patents
1366 Technologies Inc.
9 patents
What this shows 1366 holds 9 patents at rank #27,930, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
By rank, the assignees closest to #27,930 in granted patent volume.
Other assignees with the most granted patents in 1366's primary technology class.
1366's Innovation Score vs. every tracked assignee
Composite of portfolio volume, grant velocity, technology breadth, and claim depth (0–100)
32 39th percentile higher than 39% of 49,997 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Teal-shaded recent years (2020–present) versus the 2016–2019 baseline. Full figures in the table below.
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2016 | 2 | 22.2% |
| 2017 | 2 | 22.2% |
| 2018 | 1 | 11.1% |
| 2019 | 1 | 11.1% |
| 2020 | 3 | 33.3% |
Top 12 of 12 technology areas
Overall rank by patents
#27,930
of 49,997 tracked assignees
31.8 out of 100
What to do with this data
1366 Technologies Inc.'s patent record in context - here's where to go next.
Figures reflect USPTO PatentsView grant data through May 2026; pending applications not yet granted are not counted.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.